About ReNAgade
ReNAgade is a company based in Cambridge (United States) founded in 2021 was acquired by Orna in May 2024. ReNAgade has raised $300 million across 1 funding round from investors including Orna, Turmeric Acquisition Corp and F2 Ventures. The company has 136 employees as of December 31, 2022. ReNAgade operates in a competitive market with competitors including Stoke Therapeutics, Vico, MiNA Therapeutics, Ribometrix and Creyon Bio, among others.
- Headquarter Cambridge, United States
- Employees 136 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Renagade Therapeutics Management, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of ReNAgade
Unlock access to complete
Funding Insights of ReNAgade
ReNAgade has successfully raised a total of $300M through 1 strategic funding round. The most recent funding activity was a Series A round of $300 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ReNAgade
ReNAgade has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Orna, Turmeric Acquisition Corp and F2 Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Invests in biotech firms developing life-saving drugs and technologies.
|
Locked | Locked | Locked | |
|
Technologies for producing circular RNA therapeutics are developed.
|
Locked | Locked | Locked |
Investor details for ReNAgade
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ReNAgade
Investment portfolio details for ReNAgade
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ReNAgade
Detailed financials for ReNAgade
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Renagade Comparisons
Peer comparison for ReNAgade
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ReNAgade
ReNAgade operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Stoke Therapeutics, Vico, MiNA Therapeutics, Ribometrix and Creyon Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing
|
|
| Locked | Locked | Locked |
RNA modulating therapies for genetic neurological diseases are developed.
|
|
| Locked | Locked | Locked |
Small activating RNA therapeutics are developed to restore gene function.
|
|
| Locked | Locked | Locked |
RNA-targeted drug discovery platform using three-dimensional structural analysis is provided.
|
|
| Locked | Locked | Locked |
Oligonucleotide-based drug development platform is provided using AI models.
|
Detailed competitors of ReNAgade
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Renagade
Complete news archive for ReNAgade
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReNAgade
ReNAgade was founded in 2021 and raised its 1st funding round 2 years after it was founded.
ReNAgade is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Amit Munshi is the current CEO of ReNAgade.
ReNAgade is a funded company, having raised a total of $300M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at ReNAgade is 136.
ReNAgade was founded in 2021 and is based in Cambridge, United States. RNA-based medicines are developed by the company to address various diseases. Novel RNA delivery platforms are combined to enable coding, editing, and gene insertion functionalities. Operations focus on advancing therapeutic innovations within the biotechnology sector, with emphasis on precise genetic modifications for medical applications.
ReNAgade's top competitors include MiNA Therapeutics, Vico and Stoke Therapeutics.
ReNAgade has 3 investors. Key investors include Orna, Turmeric Acquisition Corp, and F2 Ventures.